Expertise in
2
conditions

Dr. Egilius L. Spierings

Neurology
Boston Surgery Center LLC
85 1st Ave, 
Waltham, MA 
Expertise in
2
conditions
Boston Surgery Center LLC
85 1st Ave, 
Waltham, MA 

Overview

Egilius Spierings is a Neurologist practicing medicine in Waltham, Massachusetts.

Dr. Spierings is highly rated in 2 conditions, according to our data. His clinical expertise encompasses Migraine, Headache, Chronic Pain, and Tension Headache.

He is actively involved in clinical research, co-authoring 41 peer reviewed articles and participating in 10 clinical trials.

Specialties

Neurology

Licenses

Psychiatry & Neurology in MA

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
BMC HealthNet
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
Cigna
  • EPO
  • HMO
  • PPO
Commonwealth Care Alliance
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Mass General Brigham Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 6 Less Insurance Carriers -

Locations

Boston Surgery Center LLC
85 1st Ave, Waltham, MA 02451

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

Pediatric Options for Migraine Relief: A Randomized, Double-Blind, Placebo-Controlled Study of Lasmiditan for Acute Treatment of Migraine: PIONEER-PEDS1
Pediatric Options for Migraine Relief: A Randomized, Double-Blind, Placebo-Controlled Study of Lasmiditan for Acute Treatment of Migraine: PIONEER-PEDS1
Enrollment Status: Terminated
Publish Date: September 02, 2026
Intervention Type: Drug
Study Drug: Lasmiditan
Study Phase: Phase 3
A Phase 3, 12-Month, Open-Label Study of Lasmiditan in Pediatric Patients With Migraine - PIONEER-PEDS2
A Phase 3, 12-Month, Open-Label Study of Lasmiditan in Pediatric Patients With Migraine - PIONEER-PEDS2
Enrollment Status: Terminated
Publish Date: June 25, 2026
Intervention Type: Drug
Study Drug: Lasmiditan
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Patients 6 to 17 Years of Age With Episodic Migraine - the REBUILD-1 Study
A Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Patients 6 to 17 Years of Age With Episodic Migraine - the REBUILD-1 Study
Enrollment Status: Active_not_recruiting
Publish Date: January 26, 2026
Intervention Type: Drug
Study Phase: Phase 3
Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate LY3016859 for the Treatment of Chronic Low Back Pain
Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate LY3016859 for the Treatment of Chronic Low Back Pain
Enrollment Status: Completed
Publish Date: November 30, 2023
Intervention Type: Drug
Study Drug: LY3016859
Study Phase: Phase 2
A 12-month Prospective, Randomized, Interventional, Global, Multi-center, Active-controlled Study Comparing Sustained Benefit of Two Treatment Paradigms (AMG334 qm vs. Oral Prophylactics) in Adult Episodic Migraine Patients
A 12-month Prospective, Randomized, Interventional, Global, Multi-center, Active-controlled Study Comparing Sustained Benefit of Two Treatment Paradigms (AMG334 qm vs. Oral Prophylactics) in Adult Episodic Migraine Patients
Enrollment Status: Completed
Publish Date: November 18, 2023
Intervention Type: Drug
Study Drugs: Erenumab, Oral Prophylactic
Study Phase: Phase 4
Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate LY3016859 for the Treatment of Diabetic Peripheral Neuropathic Pain
Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate LY3016859 for the Treatment of Diabetic Peripheral Neuropathic Pain
Enrollment Status: Completed
Publish Date: November 14, 2023
Intervention Type: Drug
Study Drug: LY3016859
Study Phase: Phase 2
Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate LY3016859 for the Treatment of Osteoarthritis
Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate LY3016859 for the Treatment of Osteoarthritis
Enrollment Status: Completed
Publish Date: November 14, 2023
Intervention Type: Drug
Study Drug: LY3016859
Study Phase: Phase 2
EMERGE: A Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Single Doses of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine
EMERGE: A Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Single Doses of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine
Enrollment Status: Completed
Publish Date: June 29, 2023
Intervention Type: Drug
Study Phase: Phase 3
A Long-Term, Open-Label Study to Evaluate the Safety of M207 (Zolmitriptan Intracutaneous Microneedle System) in the Acute Treatment of Migraine
A Long-Term, Open-Label Study to Evaluate the Safety of M207 (Zolmitriptan Intracutaneous Microneedle System) in the Acute Treatment of Migraine
Enrollment Status: Completed
Publish Date: August 19, 2020
Intervention Type: Drug
Study Phase: Phase 3
Randomized, Double-blind, Multi-center, Parallel-group, Dose-ranging Comparison of the Safety and Efficacy of the ZP-Zolmitriptan Intracutaneous Microneedle Systems to Placebo for the Acute Treatment of Migraine
Randomized, Double-blind, Multi-center, Parallel-group, Dose-ranging Comparison of the Safety and Efficacy of the ZP-Zolmitriptan Intracutaneous Microneedle Systems to Placebo for the Acute Treatment of Migraine
Enrollment Status: Completed
Publish Date: March 13, 2018
Intervention Type: Drug
Study Phase: Phase 2/Phase 3
View 9 Less Clinical Trials

41 Total Publications

Celecoxib Oral Solution and the Benefits of Self-Microemulsifying Drug Delivery Systems (SMEDDS) Technology: A Narrative Review.
Celecoxib Oral Solution and the Benefits of Self-Microemulsifying Drug Delivery Systems (SMEDDS) Technology: A Narrative Review.
Journal: Pain and therapy
Published: March 22, 2023
Similar Doctors
Expertise in
24
conditions
Expertise in
24
conditions
Referral may be required
Before you request

Dana-Farber Cancer Institute, Center For Neuro-Oncology

450 Brookline Avenue, 
Boston, MA 
 (9.1 miles away)
617-632-2166
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Patrick Wen is a Neurologist practicing medicine in Boston, Massachusetts. Dr. Wen is highly rated in 24 conditions, according to our data. His clinical expertise encompasses Glioblastoma, Astrocytoma, Glioma, and Brain Tumor. Dr. Wen is board certified in Neurology and Neuro-Oncology. Dr. Wen is currently accepting new patients.

Expertise in
38
conditions
Expertise in
38
conditions
Referral may be required

Office

55 Fruit St # 9, 
Boston, MA 
 (10.4 miles away)
617-724-8770
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Scott Plotkin is a Neurologist practicing medicine in Boston, Massachusetts. Dr. Plotkin is highly rated in 38 conditions, according to our data. His clinical expertise encompasses Schwannomatosis, Neurofibromatosis Type 2 (NF2), Neurofibromatosis, and Acoustic Neuroma. Dr. Plotkin is currently accepting new patients.

Expertise in
77
conditions
Expertise in
77
conditions
Referral may be required

Massachusetts General Hospital

55 Fruit St, 
Boston, MA 
 (10.5 miles away)
617-726-3216
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Jeremy Schmahmann is a Neurologist practicing medicine in Boston, Massachusetts. Dr. Schmahmann is highly rated in 77 conditions, according to our data. His clinical expertise encompasses Spinocerebellar Ataxia, Acute Cerebellar Ataxia, Olivopontocerebellar Atrophy, Posterior Fossa Decompression, and Gastrostomy. Dr. Schmahmann is currently accepting new patients.

Frequently Asked Questions about Dr. Egilius L. Spierings

How do I make an appointment with Dr. Egilius L. Spierings?

You can book an appointment with Dr. Egilius L. Spierings by calling their office at 781-647-7246. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Egilius L. Spierings a top-rated expert for Migraine?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Egilius L. Spierings is classified as an Distinguished expert for Migraine, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Egilius L. Spierings specialize in?

While Dr. Egilius L. Spierings is a Neurology, they have specific expertise in Migraine, Headache, and Chronic Pain. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Neurology.

Does Dr. Egilius L. Spierings participate in research or clinical trials?

Yes. Dr. Egilius L. Spierings has published 41 articles and abstracts on conditions like Migraine. You can view a list of Dr. Egilius L. Spierings's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Egilius L. Spierings accept my insurance?

Dr. Egilius L. Spierings accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 781-647-7246 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Spierings's expertise for a condition
ConditionClose
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile